Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
Biologics Pricing Report
Oral Solid Dose Market Report
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Phase III
18 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
Clinical Trials
Soligenix Announces Positive Recommendation on its Phase 3 Clinical Trial for the Treatment of Oral Mucositis
PR-M09-19-NI-007
Phase III
GSK Announces Positive Headline Results in Phase 3 PRIMA Study of ZEJULA (niraparib) For Patients with Ovarian Cancer
PR-M07-19-NI-039
Phase III
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
PR-M07-19-NI-023
Phase III
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
PR-M05-19-NI-022
Drug Development
New NASH Treatment Achieves Positive Phase III Results
PAO-M02-19-NI-018
Clinical Trials
Avapritinib Receives Phase III Clinical Trial Approval for GIST in China
PR-M02-19-NI-038
Phase III
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study: Advances in Sleep and Circadian Science
PR-M02-19-NI-010
Oncology
Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer
PR-M01-19-NI-012
Clinical Trial
Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome
PR-M12-18-NI-028
Biosimilars
Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
PR-M06-18-NI-100
Clinical Trials
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
PR-M04-18-NI-51
Clinical Trials
First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer
PR-M04-18-NI-33
Clinical Trials
Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy
PR-M04-18-NI-006
Clinical Trials
Aimmune’s AR101 Meets Phase 3 Endpoints
PAO-M02-18-NI-020
Oncology
Device Plus Drug Approved for Bladder Cancer Detection
PAO-M02-18-NI-018
Phase 3
Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
PR-M02-18-NI-61
Oncology
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
PR-M01-18-NI-074